G antigen 8 (GAGE8) (GAGE8)

G antigen 8 (GAGE8) is a member of the GAGE family of cancer-testis antigens (CTAs), which are proteins typically expressed only in the germ cells of the human testis but aberrantly expressed in various malignancies (UniProt: Q9UEU5) [1]. As a CTA, GAGE8 is highly immunogenic and represents a promising target for cancer immunotherapy, including cancer vaccines and adoptive T-cell therapies (Gjerstorff & Ditzel, 2008) [3]. Its expression has been detected in a wide range of cancers, such as melanoma, lung cancer, and breast cancer, where it may contribute to tumor cell survival and resistance to apoptosis (The Human Protein Atlas) [4]. Because its normal expression is restricted to the immune-privileged environment of the testis, targeting GAGE8 is expected to have minimal off-target toxicity in healthy tissues (NCBI: Gene ID 2579) [2]. Current therapeutic strategies focus on leveraging the protein's ability to elicit a robust cytotoxic T-lymphocyte response to selectively eliminate GAGE8-positive tumor cells (PubMed: 18416845) [3]. The high degree of sequence similarity among GAGE family members suggests that therapies targeting GAGE8 may also provide broader coverage against other GAGE-expressing tumor cells, although this also necessitates careful screening for potential cross-reactivity (UniProt: Q9UEU5) [1].

Other names

GAGE-8 (UniProt: Q9UEU5) [1]Cancer/testis antigen 4.8 (UniProt: Q9UEU5) [1]CT4.8 (UniProt: Q9UEU5) [1]G antigen 2E (UniProt: Q9UEU5) [1]

Induction of T-cell mediated immune response and cytotoxic T-lymphocyte (CTL) activation against cells presenting GAGE8-derived peptides on MHC class I molecules (PubMed: 18416845) [3]